Stockscreener 앱 받기
9.87
0.00%
0.00
전일 마감가:
$9.87
열려 있는:
$9.88
하루 거래량:
23,977
Relative Volume:
0.95
시가총액:
$647.23M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-0.10%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$9.87
$9.89
1주일 범위
$9.87
$9.89
52주 변동 폭
$9.87
$9.89
Drugs Made In America Acquisition Ii Corp Stock (DMII) Company Profile
명칭
Drugs Made In America Acquisition Ii Corp
전화
954-870-3104
주소
1 EAST BROWARD BOULEVARD, FORT LAUDERDALE
DMII을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DMII
Drugs Made In America Acquisition Ii Corp
|
9.87 | 647.23M | 0 | 0 | 0 | 0.00 |
|
XXI
Twenty One Capital Inc
|
11.50 | 4.04B | 0 | 0 | 0 | 0.00 |
|
LION
Lionsgate Studios Corp
|
8.19 | 2.39B | 3.13B | -174.20M | -111.20M | -0.6937 |
|
CCCX
Churchill Capital Corp X
|
14.91 | 764.09M | 0 | 0 | 0 | 0.00 |
|
BCSS
Bain Capital Gss Investment Corp
|
10.12 | 589.84M | 0 | 0 | 0 | 0.00 |
Drugs Made In America Acquisition Ii Corp 주식(DMII)의 최신 뉴스
Pfizer Inc. - Britannica
Layoff Tracker: Pfizer, Geron Downsize To Streamline Costs - BioSpace
Aug Movers: Is Drugs Made In America Acquisition Corp stock a top momentum playWeekly Volume Report & Free Technical Pattern Based Buy Signals - moha.gov.vn
What analysts say about Drugs Made In America Acquisition Corp stockDividend Yield Trends & Exceptional Profit Portfolio - earlytimes.in
Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) is largely controlled by institutional shareholders who own 79% of the company - Yahoo Finance
Hims & Hers acquires Livewell in Canada in anticipation of generic Ozempic - The Globe and Mail
Drugs Made In America Appoints New CFO - MSN
Drugs Made In America Acquisition II Corp. Announces the Separate Trading of its Ordinary Shares and Rights Commencing December 3, 2025 - Markets Financial Content
Prescription Drug Costs - Britannica
BMK Pharma To Open $50M U.S. HQ and Pharmaceutical Facility in Allen - Dallas Innovates
CVS Pharmacy Completes Acquisition of Rite Aid Assets - Progressive Grocer
FDA declares Novo Nordisk plant, key to drug manufacturing for some biotechs, out of compliance - statnews.com
Trump Wants to Overhaul Drug Sales. A Company Tied to His Son Stands to Benefit | World News - Hindustan Times
Canadian tech helped U.S. strike alleged Venezuelan drug boats: report - CBC
Exclusive: Trump targets deals in pharma, AI, energy, mining before midterm elections - Reuters
Drugs Made In America Acquisition II Corp. closes $500 million IPO - Investing.com
Drugs Made In America $500M In IPO Marks 2025’s Biggest SPAC Debut - USA Herald
Celltrion buys Eli Lilly’s New Jersey plant for $330 million - The Korea Economic Daily Global Edition
Kenvue, the Company Behind Tylenol, Tries to Navigate Its Latest Crisis - The New York Times
$10B Domestic Drug Production Deal: PharmAGRI and Tesla to Deploy 10,000 Robots for US Prescription Drugs - Stock Titan
10,000 Tesla Robots to Power US Pharma Manufacturing: Bright Green's Merger Creates Sovereign Drug Platform - Stock Titan
U.S. Drugmakers Warn White House of Chaos as Trump Weighs Curbs on China - The New York Times
Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) is definitely on the radar of institutional investors who own 38% of the company - Yahoo Finance
CSL's Venofer finally faces generic competition as FDA clears copycats from Viatris, Sandoz and Amphastar - Fierce Pharma
UPDATED: Most expensive drugs in the US in 2025 - Fierce Pharma
Updated: AstraZeneca reports revenue growth, pipeline tweaks as it ponders price cuts, direct-to-patient sales - Endpoints News
Pharmalittle: We're reading about Sarepta resisting FDA over Elevidys, agency naming top drug regulator, and more - statnews.com
US FDA approves Regeneron's blood cancer therapy - Reuters
US pharma bets big on China to snap up potential blockbuster drugs - Reuters
Markets News, May 12, 2025: Stocks Surge After US, China Agree to Slash Tariffs; Dow Jumps Nearly 1,200 Points as Amazon, Apple, Nike Soar - Investopedia
The top 20 pharma companies by 2024 revenue - Fierce Pharma
ICR, the Leading SPAC Communications and Advisory Firm, Publishes its Q1 2025 SPAC Market Update & Outlook - Business Wire
Drugs Made In America Acquisition Corp. (DMAA) reports earnings - qz.com
Bright Green Corporation Announces the next steps for the completion of its restructuring plan - GlobeNewswire
The top 10 drugs losing US exclusivity in 2025 - Fierce Pharma
7 Best Weight Loss Drug Stocks to Buy in 2025 - US News Money
Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion | Eli Lilly and Company - Eli Lilly
A little-known Chinese company made a drug that beat the world’s biggest-selling medicine - CNN
Bright Green Corporation Charts New Course with Restructuring and API Manufacturing Plan - Cannabis Science and Technology
Popular cannabis brand declares Chapter 11 bankruptcy - thestreet.com
Hims & Hers Acquires US-based Peptide Facility - Hims Investor Relations
SPAC Alert: Key Trading Change Coming for Drugs Made In America UnitsWhat Investors Should Track - Stock Titan
U.S. investors, Big Pharma race to find new medicines in China - CNBC
What a $2 Million Per Dose Gene Therapy Reveals About Drug Pricing - ProPublica
Bain throws down $3.3B to acquire Japan's Mitsubishi Tanabe Pharma - Fierce Pharma
Merck touts 20 new ‘blockbuster’ drugs in development with $50 billion potential - Fortune
IPO NewsUS IPO Weekly Recap: Active January closes out with several sizable IPOs - renaissancecapital.com
Drugs Made In America Acquisition Corp. Completes $200 Million IPO on Nasdaq - Nasdaq
Drugs Made In America SPAC Nets $200M To Buy Pharma Biz - Law360
Top 10 most anticipated drug launches of 2025 - Fierce Pharma
Danone’s yogurt sales surge among US consumers using GLP-1 drugs - Food Dive
Drugs Made In America Acquisition Ii Corp (DMII) 재무 분석
Drugs Made In America Acquisition Ii Corp (DMII)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.20%
0.10%
자본화:
|
볼륨(24시간):